Loading...
7 results
Search Results
Now showing 1 - 7 of 7
- A pilot study on the efficacy of a single intra-articular administration of Triamcinolone Acetonide, Hyaluronan, and a combination of both for clinical management of osteoarthritis in Police Working DogsPublication . Alves, João C.; Santos, Ana; Jorge, Patrícia; Lavrador, Catarina; Carreira, L.MiguelObjectives: To describe and compare the use and effectiveness of a single intra-articular injection (IA) of triamcinolone acetonide (TA), hyaluronan (HA), and a combination of both (TA+HA) in police working dogs with natural occurring hip osteoarthritis (OA). Study Design: Prospective, randomized, single-blinded study. Sample Population: Thirty animals with naturally occurring hip OA. Methods: Animals were randomly divided in three groups: GT, treated with 20 mg of TA per hip joint; GH, treated with treated 20 mg of HA per hip joint; and GTH, treated with a combination of 20 mg of TA and 20 mg of HA per hip joint. Response to treatment, measured by the Canine Brief Pain Inventory (divided in Pain Interference Score-PIS and Pain Severity Score-PSS) and the Hudson Visual Analog Scale (HVAS), was evaluated in seven different time points: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5, and T6 (after 1, 2, 3, 4, and 5 months, respectively). Results were compared using a Kruskal-Wallis test or a Wilcoxon signed ranks test, and p < 0.05 was set. Results: Comparing results of the different time points considered with T0, significant differences were registered in GH at T1 for HVAS (p = 0.03) and PIS (p = 0.04); and in GTH at T1 (p = 0.05 for HVAS and p < 0.05 for PIS), T2 (p < 0.04 for PIS), T3 (p < 0.03 for HVAS and p = 0.05 for PIS), T4 (p < 0.03 for HVAS and p < 0.05), and T5 (p < 0.05 for HVAS). No significant differences were found between groups when comparing scores in each time point. Individual treatment is considered successful with a reduction of >= 1 for PSS or >= 2 for PIS. In GTH, treatment was successful in four animals between T1 and T5 (40%, n = 10) and three at T6-T7 (30%, n = 10) for PSS and three animals of GTH at T1 (30%), two at T2 (20%), three between T3 and T4 (30%), and two between T5 and T7 (20%)
- A first report on the efficacy of a single intra-articular administration of blood cell secretome, triamcinolone acetonide, and the combination of both in dogs with osteoarthritisPublication . Alves, JC; Santos, A; Jorge, P; Carreira, L.MiguelBackground: Osteoarthritis represents a signifcant welfare problem for many dogs, with limited therapeutic options other than palliative pain control. To evaluate the efect of the intra-articular administration of blood cell secretome and triamcinolone, 15 dogs with bilateral hip osteoarthritis were randomly assigned to a blood cell secretome (BCSG, n=5), triamcinolone (TG) or their combination group (BCS+TG, n=5). BCSG received a single intra-articular administration of 3 ml of blood cell secretome, TG 0.5 ml of triamcinolone acetonide 40 mg/ml, and BCS+TG received the combined products. The volume to administrate was corrected to 3.5 ml with saline. On days 0, 8, 15, 30, 60, 90, 120, 150, and 180, a copy of the Canine Brief Pain Inventory (divided into pain interference score—PIS and Pain Severity Score—PSS), Liverpool Osteoarthritis in Dogs (LOAD), Hudson Visual Analogue Scale (HVAS), and Canine Orthopedic Index (COI, divided into function, gait, stifness, and quality of life) was completed. Results were analyzed with the Kruskal–Wallis test and the Kaplan–Meier estimators were conducted and compared with the Log Rank test, p<0.05. Results: Animals in the sample had a mean age of 9.0±2.9 years and a bodyweight of 28.8±4.1 kg. Hips were classifed as moderate (8) and severe (7) osteoarthritis. No diferences were found between groups at T0 regarding considered evaluations. Signifcant diferences were observed between groups in pain scores from+8d-+150d, with BCS+TG exhibiting better results. The same was observed for HVAS and LOAD, from+8d-+120d. Improvements were also observed in several dimensions of the COI. Kaplan–Meier estimators showed that BCS+TG produced longer periods with better results, followed by BCSG and TG. Conclusion: The intra-articular administration of blood cell secretome improved the clinical signs and scores of several clinical metrology instruments in dogs with hip OA, particularly when combined with triamcinolone. Further studies are required.
- A comparison of intra-articular blood cell secretome and blood cell secretome with triamcinolone acetonide in dogs with osteoarthritis: a crossover studyPublication . Alves, JC; Santos, Ana; Jorge, Patricia; Carreira, L.MiguelSimple Summary Osteoarthritis is a very common joint disease in dogs. There are multiple treatments described for the disease, but there is still a need for treatments that change disease progression while managing symptoms. For that reason, a growing interest has arisen around biological treatments such as Blood Cell Secretome. The goal of this study was to compare the intra-articular administration of Blood Cell Secretome to its combined administration with triamcinolone in dogs with hip osteoarthritis. Our results show that Blood Cell Secretome improves the overall condition of OA patients and that the combination with triamcinolone lead to faster and longer-lasting improvements. Osteoarthritis (OA) is a growing welfare problem for dogs and a challenge to manage for the clinician, and most therapeutic options aim to control pain. In a randomized, double-blinded, placebo-controlled, 2-way, 2-period crossover study, we aimed to evaluate the use of Blood Cell Secretome (BCS) administrated intra-articularly, with or without the combination with triamcinolone, in dogs with bilateral hip OA. BCS is an acellular orthobiologic containing anti-inflammatory and anabolic proteins produced from the patient's own blood through extended coagulation in a defined environment. Fifteen dogs were initially assigned to a BCS group (BCSG, n = 5), a triamcinolone group (TG, n = 5), or a combination group (BCS+TG, n = 5). All had bilateral hip OA. After a 180-day follow-up, the crossover was performed with BCSG (n = 7) and BCS+TG (n = 7). BCSG received a single intra-articular administration of 3 mL of Blood Cell Secretome, and BCS+TG received BCS plus 0.5 mL of triamcinolone acetonide (40 mg/mL). The volume in BCSG was corrected to 3.5 mL with saline. In all patients, both hips were treated. For treatment follow-up, a copy of the Canine Brief Pain Inventory (divided into pain interference score-PIS and Pain Severity Score-PSS), Liverpool Osteoarthritis in Dogs (LOAD), and Canine Orthopedic Index (COI, divided into function, gait, stiffness, and quality of life) was completed on days 0, 8, 15, 30, 60, 90, 120, 150, and 180. Results were analyzed with the Mann-Whitney U test, effect size, and Kaplan-Meier estimators, followed by the log-rank test. p was set at <0.05. Patients of the sample had a mean age of 9.6 +/- 2.9 years and a body weight of 29.2 +/- 3.9 kg. Seven hips were classified as severe osteoarthritis, and eight were classified as moderate. No differences were found between groups at T0. Significant differences were observed in PSS scores at +8d, with BCS+TG exhibiting better results. PIS, PSS, LOAD, stiffness, and function scores were also lower in BCS+TG from +15 to +60d. The two groups showed similar improvements from +90 to +120d. Kaplan-Meier estimators showed that dogs in BCS+TG showed clinically-important differences for longer, despite a positive result in BCSG. The intra-articular administration of BCS alone was able to improve the overall condition of OA patients. Its combined use with triamcinolone acetonide lead to a faster and longer-lasting improvement in pain scores
- Evaluation of two therapeutic options for naturally occurring osteoarthritis in police working dogsPublication . Alves, J. C.; Santos, Ana; Jorge, Patricia; Lavrador, Catarina; Carreira, L.MiguelABSTRACT - To compare the effectiveness of intra-articular (ia) methylprednisolone-acetate and triamcinolone acetonide in the management of naturally occurring hip os-teoarthritis, 20 dogs were divided into two groups according to the drug injected per joint: gt (20 mg of triamcinolone acetonide) and gmpa (40 mg methyl-prednisolone). Animals were treated at T0 (treatment day), and further evalu-ations were conducted at T1 (15 days after treatment), T2, T3, T4, T5, T6, and T7 (one, two, three, four, five, and six months after treatment respectively). Response to treatment was measured using the Canine Brief Pain Inventory and Hudson Visual Analogue Scale, p < 0.05.Treatment was successful in reducing the pain severity score in two an-imals of gt at T1 (20 %), three at T2–T3 (37.5 %), and two at T4–T7 (28.6 %). For gmpa, treatment was successful in two animals at T1 (20 %), four at T2 (40 %), three at T3 (30 %), and two at T4–T5 (20 %). When considering pain interference score, treatment was successful in two animals in both gt and gmpa from T1–T7. No significant differences were observed when comparing each moment with T0 or between groups. Intra-articular ta and mpa injection may be a treatment option for some patients, as some benefited from ia with ta and mpa.
- Effect of a single intra-articular high molecular weight hyaluronan in a naturally occurring canine osteoarthritis model : a randomized controlled trialPublication . Alves, J. C.; Moniz Pereira dos Santos, Ana Margarida; Jorge, Patrícia; Vieira Branco Lavrador, Catarina Falcão Trigoso; Carreira, L.MiguelBackground Osteoarthritis (OA) is a complex joint disease and chronic pain source, affecting a patient's quality of life and posing a financial burden. As the dog is considered a nearly ideal species for translation research of human OA and the most used model for research, exploring spontaneous dog OA under the One Health/One Medicine concept can improve both humans and dogs' health and well-being. Methods In a clinical treatment experiment, forty (N=40) joints were selected and randomly assigned to a control group (CG), which received 0.9% NaCl or a treatment (HG), which received Hylan G-F 20. Evaluations were performed on treatment day (T0), 8, 15, 30, 90, and 180 days post-treatment. They consisted of four different Clinical Metrology Instruments (CMI), evaluation of weight distribution, joint range of motion, thigh girth, radiographic and digital thermography imaging, synovial fluid interleukin-1 (IL-1), and C-reactive protein concentrations. Results were compared with repeated measures ANOVA, with a Huynh-Feldt correction, Paired samples T-test, or Wilcoxon signed-ranks test, with pResults Patients had a mean age of 6.5 +/- 2.4 years and a bodyweight of 26.6 +/- 5.2kg, and joints graded as mild (n=28, 70%), moderate (n=6, 15%), and severe OA (n=6, 15%). No differences were found between groups at T0. Symmetry index and deviation showed significant improvements in HG from 30 days (p<0.01) up to 180 days (p=0.01). Several CMI scores, particularly pain scores, improved from 90 to 180 days. Radiographic signs progressed in both groups. In both groups, increasing body weight and age corresponded to worse clinical presentation. IA hyaluronan administration produced increased lameness in six cases, which resolved spontaneously. Conclusions This study characterizes the response to treatment with Hylan G-F 20, which can produce significant functional and pain level improvements in patients with OA, even those with factors related to worse response to treatment.
- A report on the use of a single intra-articular administration of autologous platelet therapy in a naturally occurring canine osteoarthritis model : a preliminary studyPublication . Alves, João C.; Santos, A.; Jorge, P.; Lavrador, C.; Carreira, L.MiguelBackground: Osteoarthritis (OA) represents a significant burden to societies, as it affects quality of life, performance and poses a large healthcare cost. We aimed to describe the use of a single intra-articular (IA) injection of an autologous platelet therapy in the management of osteoarthritis (OA) in a naturally occurring canine model. Methods: Fifteen police working dogs with bilateral hip OA were treated with 3 ml of platelet concentrate per hip joint, produced with the V-PET kit. Response to treatment was measured by the Canine Brief Pain Inventory (CBPI, divided in pain interference score – PIS, and Pain Severity Score - PSS), Liverpool Osteoarthritis in Dogs (LOAD), Canine Orthopedic Index (COI, divided in four dimensions: function, gait, stiffness and quality of life - QOL) and the Hudson Visual Analogue Scale (HVAS). Seven different time points were considered: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5 and T6 (after 1, 2, 3, 4 and 5 months respectively). Results from each evaluation moment were compared with T0 with a Paired Samples T-Test, and a p < 0.05 was set. Results: Significant differences were observed at T1 (p < 0.01 for HVAS, PSS, COI, Gait and QOL; p = 0.01 for PIS; p = 0.02 for Function; and p < 0.05 for Stiffness), T2 (p < 0.01 for PSS, PIS and Gait; p = 0.01 for COI; p = 0.02 for HVAS, Function and QOL; and p = 0.04 for Stiffness), T3 (p < 0.01 for HVAS, PSS, PIS, Function and Gait; p = 0.01 for COI; and p = 0.02 for QOL), T4 (p < 0.01 for PSS; p = 0.03 for PIS and Gait), T5 (p < 0.01 for COI, Function and Gait; p = 0.03 for PSS, PIS and Stiffness), T6 (p < 0.01 for PSS, Function and Gait; p = 0.04 for PIS; p < 0.05 for COI) and T7 (p < 0.01 for PSS, Function and Gait; p = 0.01 for COI; and p < 0.05 for PIS). Conclusions: Autologous platelet therapy was used without apparent harm in the subjects. A single administration produced significant improvements, which lasted several months, and therefore warrants further study.
- A randomized double-blinded controlled trial on the effects of photobiomodulation therapy in dogs with osteoarthritisPublication . Alves, João C.; Santos, Ana; Jorge, Patricia; Carreira, L.MiguelABSTRACT - OBJECTIVE To evaluate photobiomodulation therapy in dogs with bilateral hip osteoarthritis. ANIMALS 20 dogs. PROCEDURES Forty joints were assigned to a control group (CG; n = 20) or treatment group (photobiomodulation therapy [PBMT]; 20). CG received a 21-day course of meloxicam, and PBMT received treatment with a Class IV therapeutic laser over 3 weeks. Joint range of motion, thigh girth, the Canine Brief Pain Inventory (divided into pain interference score [PIS] and pain severity score [PSS]), Hudson Visual Analogue Scale, Liverpool Osteoarthritis in Dogs, and Canine Orthopedic Index (COI; divided into function, gait, stiffness, and quality of life) were evaluated before treatment, +8, +15, +30, +60, and +90 days after initial treatment. Results were analyzed with repeated measures ANOVA or Wilcoxon signed ranks test, P < 0.05. Kaplan-Meier estimators were compared with the Breslow test. RESULTS Patients had a mean age of 8.3 ± 1.9 years and body weight of 65.7 ± 12.1lb. Osteoarthritis was classified as moderate (n = 26) and severe (14). No differences were found at time 0. Better results were observed in PBMT at +8 days (P = 0.01 for PSS, P = 0.04 for function and COI), +15 days (P = 0.01 for PSS and function, P = 0.02 for PIS and function, P = 0.03 for COI and P = 0.04 for Liverpool Osteoarthritis in Dogs [LOAD]) and +30 days (P =0.01 for function and gait, P = 0.02 for COI, and P = 0.04 for PIS, PSS, and LOAD). Joint range of motion improved in PBMT from +15 to 90 days. Kaplan-Meier estimators showed that PBMT produced longer periods with better results. CLINICAL RELEVANCE PBMT reduced pain levels and improved clinical findings in dogs with hip osteoarthritis.